IRENE GAVRAS, M. D.; LOUIS G. GRAFF, M.D.; BURTON D. ROSE, M.D.; JOHN M. McKENNA, M.D.; HANS R. BRUNNER, M.D.; HARALAMBOS GAVRAS, M.D.
Chronic inhibition of the angiotensin-converting enzyme has been used successfully in treating hypertension and congestive cardiac failure (1-4) over the past 3 years. The only oral angiotensin-converting enzyme inhibitor presently available for clinical use, captopril (Capoten, E. R. Squibb & Sons, Inc., Princeton, New Jersey), has been associated with a number of adverse reactions. These include skin rashes, sometimes preceded by fever, often accompanied by eosinophilia and lymphopenia; proteinuria, usually observed in patients with primary renal parenchymal disease; alteration or loss of taste; and recently, four cases of leukopenia with agranulocytosis (5-8). All these were transient and reversible by decreasing
GAVRAS I, GRAFF LG, ROSE BD, McKENNA JM, BRUNNER HR, GAVRAS H. Fatal Pancytopenia Associated with the Use of Captopril. Ann Intern Med. 1981;94:58–59. doi: 10.7326/0003-4819-94-1-58
Download citation file:
Published: Ann Intern Med. 1981;94(1):58-59.
Cardiology, Coronary Risk Factors, Hematology/Oncology, HIV, Hypertension.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use